Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. reports developments across a diversified biopharmaceutical business built around a core royalty portfolio, Innoviva Specialty Therapeutics, and strategic healthcare investments. Recurring updates cover royalty revenue from GSK-related respiratory products, IST commercial performance in critical care and infectious disease medicines, and capital allocation actions such as share repurchases.
Company news also includes regulatory and clinical developments for IST antibiotics, including NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea, ZEVTERA updates, medical-conference presentations, and changes in the value of strategic healthcare assets such as Armata Pharmaceuticals investments.
Innoviva (NASDAQ: INVA) reported second quarter 2026 total revenue of $119.6 million, up 19% year over year from $100.3 million. Net royalty revenue was $56.3 million, while net product sales rose 46% to $51.8 million, including U.S. sales of $36.6 million, driven mainly by GIAPREZA, XACDURO and XERAVA. Income from operations increased to $50.9 million from $48.8 million.
Net unfavorable fair value changes of $161.0 million, largely related to Armata Pharmaceuticals, led to a net loss of $83.4 million, or $1.14 per basic share. Innoviva launched wholly owned subsidiary Nortiva Bio to develop the LYNX long-acting oral drug delivery platform, signed an exclusive XACDURO licensing and distribution deal with Dr. Reddy’s Laboratories, and repurchased 1.4 million shares for $31.4 million under its $125 million buyback program. Cash and cash equivalents totaled $570.4 million at June 30, 2026.
Nortiva Bio, a clinical-stage biopharma and wholly owned subsidiary of Innoviva (NASDAQ: INVA), launched to develop long-acting oral medicines using its proprietary LYNX™ platform, which can extend dosing intervals to once monthly.
The platform, acquired from Lyndra Therapeutics in 2025, has more than 50 patents, clinical proof of concept, a successful Phase 3 study, and data from over 270 individuals. Nortiva’s lead program is a once-monthly oral contraceptive supported by a $5 million Gates Foundation grant, alongside a partnering strategy to create long-acting versions of branded and generic small-molecule drugs.
Innoviva Specialty Therapeutics (Nasdaq: INVA) signed an exclusive distribution and licensing agreement with Dr. Reddy’s for XACDURO in South and Central America, the Caribbean, Russia and CIS countries. Dr. Reddy’s will handle development, regulatory and commercialization, while Innoviva is eligible for upfront, milestone and tiered royalty payments.
Innoviva (NASDAQ: INVA) announced management will participate in two June 2026 investor events: the Goldman Sachs 47th Annual Global Healthcare Conference and BTIG Infectious Disease Day.
The Goldman Sachs fireside chat is on June 8, 2026 at 1:20 p.m. ET, with a live webcast and archived replay available via Innoviva’s investor relations website.
Innoviva (NASDAQ: INVA) reported Q1 2026 results with $98.0M total revenue, driven by a resilient royalty portfolio and IST commercial growth. Net product sales were $41.4M (37% YoY), royalty revenue from GSK was $58.6M, and net income was $186.6M ($2.52 basic EPS) including a $191.2M favorable fair-value gain. Cash totaled $603.1M. IST received FDA approval for NUZOLVENCE in Dec 2025 and expects patient availability in H2 2026. The company repurchased 971,066 shares for $20.4M in Q1 under a $125M program.
Innoviva (NASDAQ: INVA) reported strong 2025 results with total revenue of $411.3M (up 15% YoY) and net income of $271.2M (basic EPS $4.02). IST U.S. net product sales grew 47% YoY to $119.2M. Royalty revenue was $250.3M for the year.
Key corporate developments include FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea, a $125M share repurchase program, a strategic asset portfolio valued at $614.0M, and $550.9M in cash and equivalents.
Innoviva (NASDAQ: INVA) said management will take part in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 10:00 a.m. ET. The conference is virtual and the session will be webcast live.
According to the company, the live webcast is available under Events & Presentations in the Investor Relations section at https://investor.inva.com/presentations-events, and an archived replay will be posted after the event.
Innoviva (NASDAQ: INVA) announced U.S. FDA approval of NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral suspension for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents 12+ years weighing ≥35 kg.
Approval was supported by the largest Phase 3 trial ever for a new gonorrhea treatment across five countries and showed non-inferiority to current injectable therapy, including against drug-resistant strains. The company plans commercialization in H2 2026, either with a partner or independently.
Innoviva Specialty Therapeutics (NASDAQ: INVA) announced publication in The Lancet of positive Phase 3 data showing single‑dose oral zoliflodacin was non‑inferior to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea (difference 5.31%, 95% CI 1.38%–8.65%).
The trial reported comparable extragenital microbiological cure and similar safety with no serious adverse events. Zoliflodacin has QIDP designation and the FDA accepted the NDA in June 2025 with a PDUFA target action date of December 15, 2025.
Innoviva (NASDAQ: INVA) said management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025 at 4:30 p.m. Eastern Time.
A live webcast will be available under “Events & Presentations” in the company’s Investor Relations site at https://investor.inva.com/presentations-events, and an archived replay will be posted after the event.